Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baricitinib or imatinib in hospitalized COVID-19 patients: Results from COVINIB, an exploratory randomized clinical trial.
Morales-Ortega A, Farfán-Sedano AI, San Martín-López JV, Escribá-Bárcena A, Jaenes-Barrios B, Madroñal-Cerezo E, Llarena-Barroso C, Mesa-Plaza N, Frutos-Pérez B, Ruiz-Giardín JM, Duarte-Millán MÁ, Piedrabuena-García SI, Carpintero-García L, Canalejo-Castrillero E, Mora-Hernández B, García-Parra CJ, Magro-García HA, Algaba-García A, Hernández-Muniesa B, Nasarre-López B, Ontañón-Nasarre A, Domínguez-García MJ, Gómez-Santos D, Prieto-Menchero S, García de Tena J, Bermejo F, García-Gil M, Gonzalo-Pascua S, Bernal-Bello D; COVINIB Study Group investigators. Morales-Ortega A, et al. Among authors: ontanon nasarre a. J Med Virol. 2023 Feb;95(2):e28495. doi: 10.1002/jmv.28495. J Med Virol. 2023. PMID: 36639911 Clinical Trial.
Early clinical experience with imatinib in COVID-19: Searching for a dual effect.
Morales-Ortega A, Rivas-Prado L, Frutos-Pérez B, Jaenes-Barrios B, Farfán-Sedano AI, García-Parra CJ, Hernández-Muniesa B, Duarte-Millán MÁ, Madroñal-Cerezo E, Ontañón-Nasarre A, Ruiz-Giardín JM, Bermejo F, García-Gil M, Gonzalo-Pascua S, San Martín-López JV, Bernal-Bello D. Morales-Ortega A, et al. Among authors: ontanon nasarre a. J Infect. 2021 May;82(5):186-230. doi: 10.1016/j.jinf.2021.02.002. Epub 2021 Feb 5. J Infect. 2021. PMID: 33549625 Free PMC article.
Assessing Pharmacists' Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis.
Martínez-López I, Maurino J, Sanmartín-Fenollera P, Ontañon-Nasarre A, Santiago-Pérez A, Moya-Carmona I, García-Collado CG, Fernández-Del Olmo R, García-Arcelay E, Sarmiento M, Carreño Á, Pérez-Encinas M. Martínez-López I, et al. Among authors: ontanon nasarre a. Pharmacy (Basel). 2020 Apr 7;8(2):61. doi: 10.3390/pharmacy8020061. Pharmacy (Basel). 2020. PMID: 32272683 Free PMC article.
[Study of the durability of the triple antiretroviral regimens].
Martínez Sesmero JM, Sánchez-Rubio Ferrández J, Ontañón Nasarre A, Ibáñez Heras N, Montojo Guillén C. Martínez Sesmero JM, et al. Among authors: ontanon nasarre a. Med Clin (Barc). 2004 May 15;122(18):693-5. doi: 10.1016/s0025-7753(04)74358-4. Med Clin (Barc). 2004. PMID: 15171829 Spanish.